Hematology
Advertisement
A prospective study involved ultrasound imaging of patients' carotid arteries to evaluate for structural changes.
Further study is needed to determine if a particular eGFR biomarker best predicts cardiovascular risks.
Reni-cel led to hemoglobin normalization and increased fetal hemoglobin in patients with sickle cell disease.
In the phase II TRANSCEND FL trial the CAR T-cell therapy has shown good efficacy and manageable safety in MZL and FL.
The menin inhibitor oral agent achieved the KOMET-001 trial's primary endpoints and had a favorable benefit-risk profile.
An expert panel's review finds SCT has often been misattributed as the direct cause of mortality in patients who have SCT.
A study cohort with severe disease over a median follow-up of 14 months had an annualized bleeding rate of zero.
Use is also being explored for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Clinicians can use this test to help distinguish more than 60 disease subtypes from patients' normal immune response.
The new agent is on the 505(b)(2) regulatory pathway and was compared with tablet-form apixaban in 60 healthy volunteers.
Organization-level changes at hospitals and medical groups are needed to meaningfully address this longstanding issue.
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Dapsone demonstrates efficacy and acceptable safety with low costs as treatment for pediatric ITP.
Two therapies being developed for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus are affected.
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
ASH's efforts pertain to professional recruitment as well as to address unique medical issues in patient populations.
Clinicians have an important role in helping donation centers make the most of exciting advances and meet recent challenges.
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
Approval was based on data from the AGAVE-201 trial and is for use in adult and pediatric patients who weigh at least 40 kg.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.